Poulton Stuart
EVP, Chief Development Officer
Poulton Stuart has filed 7 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Jul 30, 2026.
On the most recent filing, Poulton Stuart is listed as EVP, Chief Development Officer at Karyopharm Therapeutics Inc. Inside the rolling window, Poulton Stuart reported no open-market purchases and 5 open-market sales totaling $59K in KPTI. The largest disclosed transaction in the window is a sale of 5,101 KPTI shares on Mar 2, 2026, worth $48K.
Companies traded
Other insiders at KPTI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$59K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Poulton Stuart made?
Poulton Stuart has filed 7 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does Poulton Stuart trade?
Poulton Stuart has filed SEC Form 4 disclosures for 1 company, including KPTI.
When was Poulton Stuart's most recent SEC Form 4 filing?
Poulton Stuart's most recent SEC Form 4 filing on Tracefour is dated Jul 30, 2026.
What is Poulton Stuart's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Poulton Stuart is listed as EVP, Chief Development Officer.
What is Poulton Stuart's total buy and sell value in the current window?
Inside the rolling retention window, Poulton Stuart bought $0 and sold $59K based on SEC Form 4 filings.
What was Poulton Stuart's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,101 KPTI shares on 2026-03-02, worth $48K, per SEC Form 4 filings.